“Benefit of Using Renal Sodium-Glucose Cotransporter Inhibitors 2 (iSGLT-2) in Patients With Type 2 Diabetes Mellitus and Heart Failure”. Electronic Journal Collection Health, vol. 12, no. 9, Sept. 2020, p. e4349, https://doi.org/10.25248/reas.e4349.2020.